-
Osaka channels NBA icon Iverson to reach US Open second round
-
US to press G20 on light-touch AI regulation
-
Fast-fashion giant Shein plunges 10% on Hong Kong debut
-
2 die in Grand Canyon flash flood, only 1 person unaccounted for
-
South Korea hire former Spain boss Moreno as interim coach
-
US Army Secretary Driscoll submits resignation: White House
-
China-Taiwan friction clouds Pacific summit
-
Oil extends gains, stocks drop as Trump issues fresh Iran warning
-
Two dead after stabbing in New York's Times Square
-
Tsitsipas says Kyrgios's positive cocaine test 'kind of expected'
-
Anthropic signs $35B computing deal with startup backed by Nvidia
-
In Japan's mountains, a different way to manage bears
-
Drones in Ithaca: Azov's Odyssey turns Ukraine war into modern myth
-
Middle East war a boon for UAE defence giant with global ambitions
-
Boat builders keep Pakistan's fishing heritage afloat
-
Former gang member found guilty of murdering Tupac Shakur
-
Australia axe Labuschagne for Zimbabwe, South Africa ODI series
-
Top-seeded Zverev opens US Open campaign
-
Heavy rain at Grand Canyon after flood kills 2, dozen missing
-
US regulator, 22 states accuse Amazon of 'manipulating' ad auctions: lawsuit
-
Kushner blames soccer power struggle for World Cup plan collapse
-
TRON Founder Justin Sun Shares Outlook on Bitcoin, Stablecoins and Global Finance at Bitcoin Asia 2026
-
Buoyant Alcaraz shakes off nerves to advance at US Open
-
Tributes to 'eternal' Messi on Argentina retirement
-
US draws European pushback with Russia G20 finance invite
-
Arteta hails Arsenal's 'finishers' after Saka kills off Villa
-
Jury begins deliberations in Tupac Shakur murder trial
-
Yamal, Raphinha bag braces as Barcelona rout Rayo
-
US Supreme Court allows Trump ballroom project to proceed
-
Alcaraz makes winning return at US Open, Sabalenka safely through
-
Trump says US reviewing position on Falkland Islands
-
Everton agree to sign Monaco's Balogun: reports
-
Saka strikes as flawless Arsenal punish troubled Villa
-
Milei calls for F1 to return to Argentina
-
Oil prices surge on renewed fighting in US-Iran war
-
Alcaraz wins US Open first-round match after injury layoff
-
Cycling superstar Pogacar has surgery after Vuelta crash
-
Kyiv orders heightened security amid intense Russian drone strikes
-
Man City agree deal for Everton's Ndiaye
-
Sabalenka kickstarts US Open three-peat bid as Fils crashes out
-
Apple CEO Tim Cook gives nod to founder Steve Jobs in final memo
-
Fils upset by resurgent Tsitsipas at US Open
-
Russian finance minister makes unexpected appearance at G20
-
Trump says AI data center opponents want to be 'backwards and poor'
-
Happy to be back in NY, Sabalenka advances
-
Pakistan ditch coaches, send seven players home after England defeats
-
Naomi Watts to receive lifetime award at top Spain film fest
-
Galliano pulls Met Gala exhibit after antisemitism backlash
-
Jury hears closing arguments in Tupac Shakur murder trial
-
Afghan people should 'not be abandoned': top Red Cross official
Welcome to DEA Judge McLooney's Marijuana Kangaroo Court-DEA Grants Itself a Favor, Denies MMJ Cannabis Drug Relief
While Patients Suffer, DEA Manipulates Due Process to Cover Its Cannabis Crimes. The DEA blocking federally compliant pharmaceutical research is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice.
WASHINGTON, D.C. / ACCESS Newswire / July 15, 2025 / In a move that underscores everything wrong with the Drug Enforcement Administration's rogue administrative machinery, Chief Administrative Law Judge John J. Mulrooney II-dubbed "Judge McLooney" by critics-has granted the DEA government counsel's request for extra time to respond to MMJ BioPharma Cultivation's legal exceptions.
The problem? MMJ was denied a similar extension just weeks earlier. Welcome to DEA's version of justice , where the rules are rewritten on the fly- but only when it benefits the government.
The Double Standard Is Blinding
MMJ BioPharma, a pharmaceutical company developing FDA-approved cannabis medicines for Multiple Sclerosis and Huntington's Disease, filed formal exceptions on July 3, 2025. These exceptions laid out a comprehensive challenge to the agency's unlawful delay, retroactive rule changes , and structurally biased adjudication system.
On the same day, the DEA asked for time to respond-and in classic inside job fashion, Judge Mulrooney approved it with a smile.

The DEA prosecutes, adjudicates, and decides its own cases .
Parties like MMJ are trapped in legal limbo for nearly seven years .
And when a registrant finally gets its day in court, the outcome is pre-determined .
"No Undue Prejudice"-Unless You're the DEA
Mulrooney's ruling attempts to justify the favoritism, claiming that the government won't "unduly prejudice" MMJ by getting extra time. Yet just weeks ago, MMJ was denied a similar request -a blatant violation of equal treatment under the law .
"This is a kangaroo court in a lab coat," said one legal analyst. "The DEA's internal ALJ process has all the fairness of a Soviet tribunal with the constitutional legitimacy of a carnival ride."
MMJ's Exceptions: A Bombshell Legal Indictment
Filed by Megan E. Sheehan, Esq. , MMJ's legal brief outlines four devastating points:
DEA's 5-Year Delay Violates Federal Statute
Under 21 U.S.C. § 823(j) and the 2022 Medical Marijuana and Cannabidiol Research Expansion Act , DEA had 60-90 days to act. Instead, it waited nearly 5 years .Retroactive Rulemaking is a Due Process Violation
MMJ's application was submitted before the "Bona Fide Supply Agreement" rule existed. Applying it retroactively created a legal Catch-22 where compliance was impossible.DEA's ALJ Process Is Structurally Unconstitutional
MMJ cites Axon v. FTC (2023) and Free Enterprise Fund v. PCAOB , arguing that DEA's ALJs are unlawfully insulated from removal and operate under an executive echo chamber .Public Interest is Being Crushed
MMJ holds FDA INDs and Orphan Drug Designation for devastating conditions. The DEA's sabotage delays critical therapies for patients who have no other hope.
It's Not Just About MMJ-It's About the Rule of Law
This is more than a regulatory dispute. It's a crisis in American administrative law:
A federal agency is violating binding Supreme Court precedent.
A regulated entity with FDA backing is being strangled by delay and deception.
And the DEA continues to block life-saving research while allowing contaminated, cartel-grown marijuana to flourish in state markets.
Enough is Enough: The Time for Reform is Now
Congress must step in. The DEA has proven time and again that it cannot regulate fairly, legally, or scientifically.
Demand the following:
Immediate granting of MMJ's DEA license
Transfer of cannabis research oversight to the FDA or NIH
Congressional hearings on the DEA's misconduct and ALJ abuses
Full accountability for Thomas Prevoznik and the Diversion Control Division
"When the DEA denies one party an extension but grants it to its own team, you no longer have an impartial courtroom-you have a farce in a black robe," said Duane Boise, CEO of MMJ BioPharma. "It's not just a clown show-it's a taxpayer-funded sabotage of patients, science, and justice."
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
N.Walker--AT